Research programme: alpha melanotropin - RELIEF THERAPEUTICS Holding

Drug Profile

Research programme: alpha melanotropin - RELIEF THERAPEUTICS Holding

Alternative Names: Alpha-msh - mondoBIOTECH; DasKloster 0210-01; DasKloster0210; DK 0210

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Class Melanocyte-stimulating hormones
  • Mechanism of Action T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Berylliosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Berylliosis

Most Recent Events

  • 31 Jul 2016 Preclinical development is ongoing in Beryllisis Switzerland
  • 31 Jul 2016 Alpha melanotropin is available for licensing in USA, France and United Kingdom as of July 2016.
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Berylliosis in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top